Project Grant HT94252410323
Award Date 7/1/24
Completion Date 6/30/28
Dollars Obligated $575K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
- The University of Minnesota has been awarded a $665,335 Project Grant from the U.S. Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on July 1, 2024, will fund research to investigate "Trapping Inhibitory Signals in Synergy with Cytokine Signaling to Maximize NK Cell Immunotherapy in Ovarian Cancer." The project, set to run through June 30, 2028, aims to develop new immunotherapy approaches for treating...
- The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $787,793 Project Grant to the Regents of the University of Minnesota to conduct research on "LEVERAGING TARGETED BIOLOGICAL COMPLEXES TO MAXIMIZE NATURAL KILLER CELL IMMUNOTHERAPY IN LUNG CANCER". The three-year award, running from July 1, 2024 to June 30, 2027, will support the university's efforts to develop innovative immunotherapy approaches for treating lung cancer, with a...
- The Regents of the University of Minnesota received a $515,187 Project Grant award from the Defense Health Agency to conduct research titled "Leveraging Reactivation of Tissue-Resident Memory T Cells in the Tumor Microenvironment for Oncolytic Virotherapy." The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical...
- Federal Project Grant Award Summary The Regents of the University of Minnesota received a $614,150 Project Grant awarded on July 1, 2025, by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The award supports a two-year research initiative titled "Enhancing Long-Term Persistence of CAR-NK Cells for Treatment of Solid Tumors," with performance through June 30, 2027, at the university's Minneapolis campus. This project addresses...
- The University of Minnesota, through its Office of Sponsored Projects Administration, was awarded a $1,521,386 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to engage the immune system to kill sarcoma through a comparative oncology approach. The 3-year grant, which began on July 15, 2023 and will be completed by July 14, 2026, supports basic, applied, and advanced biomedical research to transform healthcare for service...
- The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,243,750 Project Grant to the Regents of the University of Minnesota, doing business as the Office of Sponsored Projects Administration, to develop allogeneic, multiplex base-edited, dual-targeted gamma delta CAR-T cell therapies for the treatment of metastatic castration-resistant prostate cancer. This 3-year award, with a project period from Sep 30, 2024 to Sep 29, 2027, will...
- This Project Grant award, worth $617,868.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Regents of the University of Minnesota. The funding supports an evaluation of a novel TRIKE-PACC molecule to amplify natural killer cell function in mesothelioma, a type of cancer. The research aims to improve health outcomes for military service members, veterans, and the broader public. The award commenced on July 15, 2024 and...
- This $1,539,818.00 Department of the Army Medical Command federal Project Grant award under the Military Medical Research and Development program (CFDA 12.420) will fund research led by the Regents of the University of Minnesota to develop multiplex edited, dual CAR gamma delta T cells targeting pediatric solid tumors. The three-year project, with a performance period from November 15, 2024 to November 14, 2027, seeks to advance innovative cell-based immunotherapies for the treatment of...
- The Regents of the University of Minnesota was awarded a $1,399,812 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, with a performance period from April 1, 2025 to March 31, 2029, will fund advanced biomedical research focused on investigating outcomes and late effects in pediatric and adolescent germ cell tumor survivors. As a prominent 1862 land-grant research institution, the University of Minnesota will...
- This federal Project Grant award from the Department of the Army Medical Command (CFDA 12.420 - Military Medical Research and Development) provides $1,348,041.00 to the Regents of the University of Minnesota to develop a RET-specific proteomic assay from circulating tumor cells in lethal prostate cancer. The award began on Mar 1, 2024 and is scheduled for completion by Feb 28, 2027. This research aims to transform health care for military service members and the general public through innovative...